Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-03-20 Annual Report
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 18th fiscal year (2023) of Cellid Co., Ltd. It contains comprehensive information including company overview, history, capital changes, business activities, and financial data. This is a standard annual regulatory filing required by the Financial Supervisory Service (FSS) in South Korea, which corresponds to the '10-K' category in the provided schema. FY 2023
2024-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (장내매수 - on-market purchase) by a company executive (강창율, CEO of Cellid). This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-03-19 Korean
[기재정정]기타경영사항(자율공시) (국책과제 선정(아데노바이러스 벡터 플랫폼 기반 COVID-19 변이에 대한 다가백신 개발))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Cellid) regarding a 'Correction Report' (정정신고) for a previously disclosed government-funded research project. It details changes to the project timeline and budget due to government R&D budget cuts. Since this is a specific regulatory disclosure of a material business event that does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2024-03-15 Korean
주주총회소집공고
AGM Information Classification · 99% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Cellid Co., Ltd. It details the meeting date, location, agenda items (such as financial statement approval, board appointments, and stock option grants), and voting procedures (including electronic voting). It also includes supplementary information required for shareholders, such as director activity reports and business overviews. This document is a standard proxy statement/notice of meeting sent to shareholders to solicit votes and provide information for the upcoming Annual General Meeting. In the provided classification schema, this fits best under 'Proxy Solicitation & Information Statement'.
2024-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures, and proxy solicitation details. This document is a formal material sent to shareholders to request their votes for the meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-12 Korean
주주명부폐쇄기간또는기준일설정
M&A Activity Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for shareholder register closure, specifically for the purpose of identifying shareholders to exercise dissent rights in a small-scale merger. It does not contain the full merger agreement or financial statements, but rather serves as a formal regulatory notice. Given it does not fit into specific categories like M&A (TAR) or Dividend (DIV), and is a standard regulatory disclosure, it falls under the RNS category.
2024-03-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.